Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Evotec SE Investor Presentation 2012

Nov 8, 2012

151_ip_2012-11-08_172c9ac6-dff7-4ed7-91ee-d6690bb790bb.pdf

Investor Presentation

Open in viewer

Opens in your device viewer

{# SEO P0-1: filing HTML is rendered server-side so Googlebot sees the full text without executing JS or following an iframe to a Disallow'd CDN path. The content has already been sanitized through filings.seo.sanitize_filing_html. #}

Action Pla Gaining M an 2016 –Momentum

Forward-looking s statements

Information set forth in this presen forward-looking statements, which invo risks and uncertainties ncertainties. The forward forward-lo contained herein represent the judgemen the date of this presentation. Such statements are neither promises nor gua subject to a variety of risks and uncert which are beyond our control control, and wh ntation containsolve a number ofoking statements nt of Evotec as offorward-looking arantees, but are tainties, many of hich couldcause

actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim an obligation or ndertaking to release p blicl any undertakingpublicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

Welcome to Evoteec!

Your management team

Agenda

•Highlights Q3 2012

  • • Action Plan 2016 – Innovation Efficiency
  • EVT Execute
  • EVT Integrate
  • EVT Innovate
  • • Financial performance & growth outlook

Action Plan 2016 –Gaining Momentum

Highlights Q3 2012

Group revenues +8% to €64.2 m, p positive operating result YTD and in Q3

EVT Execute:

  • • Multi-year compound management agreement w with NIH, value of up to € 60 m
  • Contract extension with CHDI; worth up to US\$ 4 • 41 m in research payments*

EVT Integrate: EVT Integrate:

  • • Good progress in ongoing discovery alliances hig Boehringer Ingelheim and Novartis ghlighted by recent milestone achievements with
  • • Five-year, multi-target collaboration with Bayer to o fight Endometriosis* (targets provided by Bayer)

EVT Innovate:

  • • CureBeta, a collaboration between Evotec and H Janssen PharmaceuticalsHarvard University enters strategic alliance with
  • • DiaPep277 completed patient recruitment in its P Phase III clinical trial in Diabetes Type 1
  • • Roche starts Phase II clinical trial with EVT 302 i II trial in Alzheimers' disease
  • • Strategic advisory agreement with Aspireo to part tner Somatoprim
  • • Five-year, multi-target collaboration with Bayer to o fight Endometriosis* (targets provided by Evotec)

1

2

3

Strong Growth in R Revenue

Key figures overview – Sta atus first nine months 2012vs 2011

Agenda

  • •Highlights Q3 2012
  • • Action Plan 2016 – Innovation Efficiency
  • EVT Execute
  • EVT Integrate
  • EVT Innovate
  • • Financial performance & growth outlook

Innovation Efficienncy – a reminder

Action Plan 2016

Broad stand alonee execution business

Comprehensive Drug Disc covery Platform – "EVO Apps"

Highest quality ou utsourcing services

EVT Execute – Major mile estones and actions for H2

Major contract won w management 2 with NIH in compound

Three-year extension n of CHDI contract1

E i f EVT E Expansion of Ex strengthen risk share 4 xecut biliti te capabilities ed initiatives

"Faster to Decisioaligns incentives o ns" Integrate business model of both parties

Business model

Building an even s of upside opportun strong p erortfolio nities

EVT Integrate – Major mi ilestones and actions for H2

Expansion of portfoli target alliance (Bayer 1 io with strategic multi multir)

Further milestone acalliances, e.g. with Bo hievements in ongoing oehringer Ingelheim,

Novartis

Expansion of custom biotech, mid-sized an customersmer reach to even more nd large pharma

Integrated discove ery agreement with Bayer

Long-term potential from early assets and pain expertise

i
A
b
h
l
l
b
t
t
t
o
u
e
c
o
a
o
r
a
o
n		 D
l
t
e
a
e
r
m
s		 D
l
t
e
v
e
o
p
m
e
n
F
i
l
i-
t
t
t
e
e
a
r,
m
a
r
g
e
v
-y
u
•
l
l
b
i
i
h
B
t
t
c
o
a
o
r
a
o
n
a
e
r
w
y
F
d
l
o
c
s
e
o
n
n
o
e
u
v
•
f
t
t
t
r
e
a
m
e
n
s
o
r
d
i
i
t
e
n
o
m
e
r
o
s
s
G
l
f
d
l
i
h
t
o
a
o
e
e
o
p
n
g
r
e
e
v
•
l
i
i
l
d
i
d
t
c
n
c
a
c
a
n
a
e
s		 U
f
f
€
1
2
t
t
p
r
o
n
p
a
m
m
e
n
o
m
y
•
P
i
l
l
i
i
l,
l
i
i
l
t
t
o
e
n
a
p
r
e
c
c
n
c
a
c
n
c
a
•
d
l
i
l
f
t
a
n
s
a
e
s
m
e
s
o
n
e
s
o
p
u
i
l
€
8
0
t
t
t
5
o
a
p
p
p
p
r
o
m
a
e
m
x
y
y
P
i
l
l
i
f
t
t
t
t
o
e
n
a
r
o
a
a
e
s
o
p
o
y
u
•
l
d
d
b
b
l
l
d
d
i
i
i
t
t
o
o
o
e
e
g
p
e
r
c
e
n
w
u
u
-		 B
h
i
i
b
t
t
t
t
o
p
a
r
e
s
c
o
n
r
e
u
•
i
i
d
d
t
t
t
n
n
o
a
e
r
g
a
r
g
e
s
a
n
v
v
u
h
i
h
l
i
h
l
t
t
g
q
a
e
c
n
o
o
g
u
y
y
f
i
t
t
n
r
a
s
r
c
r
e
s
u
u
S
h
h
i
b
i
l
i
f
t
t
a
r
e
e
r
e
s
p
o
n
s
o
r
y
•
l
i
i
l
h
p
r
e
-c
n
c
a
r
e
s
e
a
r
c
f
h
i
i
i
l
t
t
t
t
c
a
r
a
c
e
r
s
a
o
n
o
p
o
e
n
a
l
i
i
l
d
i
d
t
c
n
c
a
c
a
n
a
e
s
B
i
i
b
l
f
l
l
a
e
r
s
r
e
s
p
o
n
s
e
o
r
a
y
•
l
i
i
l
d
l
t
c
n
c
a
e
e
o
p
m
e
n
v

A strategic pharma financial riskaportfolio without

EVT Innovate – clinical asssets

I
d
i
i
t
n
c
a
o
n		 P
t
a
r
n
e
r		 S
t
t
a
u
s		 N
i
l
t
t
e
x
m
e
s
o
n
e		 C
i
l
o
m
m
e
r
c
a
s
1
)
D
i
b
t
a
e
e
s		 /
T
E
V
A
A
d
d
n
r
o
m
e
a		 d
d
2
2
P
P
h
h
I
I
I
n
n
a
s
e
i
l
d
t
t
r
e
c
r
u
m
e
n
c
o
s
e		 F
i
l
P
h
I
I
I
d
t
n
a
a
s
e
a
a		 A
€
i
i
l
l
l
i
4
0
t
t
t
p
p
r
o
m
m
m
e
e
s
s
o
o
n
n
e
e
s
s,
r
o
a
e
s
x.
y
;
i
l
k
€
5
0
0
t
t
t
p
o
e
n
a
m
a
r
e
a
p
p
r
o
m
x.
´s
A
l
h
i
e
m
e
r
z
2
)
D
i
s
e
a
s
e		 R
h
o
c
e		 S
P
h
I
I
t
t
a
r
a
s
e		 C
l
i
f
P
h
I
I
t
o
m
p
e
o
n
o
a
s
e
P
h
I
I
I
t
t
t
t
a
s
e
s
s
a
a
r
r		 \$
A
8
2
0
i
l
t
p
p
r
o
m
m
e
s
o
n
e
s,
x.
\$
l
i
i
l
k
3
3-
b
t
t
t
t
5
r
o
a
e
s
p
o
e
n
a
m
a
r
e
n
y
;
T
i
t
t
t
t
r
e
a
m
e
n
r
e
s
s
a
n
)
3
d
i
e
p
r
e
s
s
o
n		 O
p
e
n		 P
h
I
I
a
s
e		 N
i
t
e
p
a
r
n
e
r
n
g
w		 O
p
e
n
)
4
I
i
n
s
o
m
n
a		 J
i
i
n
g
n
x		 P
h
I
I
a
s
e		 P
h
I
I
b
t
t
a
s
e
s
a
r		 M
M
i
i
l
l
l
i
t
t
t
e
e
s
s
o
o
n
n
e
e
s,
s
r
o
y
a
e
s
)
5
I
f
l
i
t
n
a
m
m
a
o
n		 C
b
o
n
a		 /
P
h
I
I
I
a
s
e		 P
h
I
I
t
t
a
s
e
s
a
r		 A
€
i
l
l
i
6
0
t
t
p
p
r
o
m
m
e
s
o
n
e
s,
r
o
a
e
s
x.
y
I
f
l
i
i
t
n
a
m
m
a
o
n
n
)
6
i
l
h
l
h
t
a
n
m
a
e
a		 P
h
I
/
I
I
a
s
e		 D
l
d
t
t
e
v
e
o
p
m
e
n
s
o
p
p
e		 M
i
l
l
i
t
t
e
s
o
n
e
s,
r
o
y
a
e
s
A
A
l
l
D
i
b
i
t
c
c
r
r
o
o
m
m
e
e
g
g
a
a
y,
y
a
e
c
R
i
h
h
t
t
t
e
n
o
p
a
y,
o
e
r
s		 A
i
s
p
r
e
o		 P
h
I
a
s
e		 P
i
t
a
r
n
e
r
n
g		 f
A
d
i
l
i
t
v
s
o
r
y
e
e
s
r
o
y
a
e
s
o
n
;
S
i
t
o
m
a
o
p
r
m

Driving value thro ugh commercial network

Aspireo agreement

i
A
b
h
l
l
b
t
t
t
o
e
c
o
a
o
r
a
o
n
u		 D
l
t
e
a
e
r
m
s		 D
l
t
e
e
o
p
m
e
n
v
S
i
d
i
t
t
r
a
e
g
c
a
s
o
r
v
y
•
t
a
g
r
e
e
m
e
n
S
d
l
d
t
t
u
p
p
o
r
e
v
e
o
p
m
e
n
a
n
•
f
i
A
i
's
t
p
a
r
n
e
r
n
g
o
s
p
r
e
o
S
i
t
o
m
a
o
p
r
m		 A
d
i
f
d
s
o
r
e
e
s
s
a
n
v
y
•
i
i
i
i
i
t
t
p
a
r
c
p
a
o
n
n
e
c
o
n
o
m
c
f
S
i
t
s
c
c
e
s
s
o
o
o
m
a
o
p
r
m
u		 S
i
(
D
G
)
i
3
1
7
3
t
o
m
a
o
p
r
m
s
a
•
l
l
i
t
t
n
e
m
o
e
c
a
r
e
n
w
u
y
i
l
t
t
t
s
o
m
a
o
s
a
n
a
n
a
o
g
e
u
U
i
i
l
l
b
i
t
t
t-
n
q
u
e
p
o
e
n
a
y
e
s
n
•

,
l
h
l
i
l
c
a
s
s
p
a
r
m
a
c
o
o
g
c
a
,
f
i
l
p
r
o
e
P
i
b
l
i
d
i
i
i
l
d
t
o
s
s
e
n
c
a
o
n
s
n
c
e
u
•
l
i
i
d
a
c
r
o
m
e
g
a
c
a
r
c
n
o
y
,
d
C
h
i
's
t
m
o
r
s
a
n
s
n
g
u
u
u
,
d
i
s
e
a
s
e
S
i
i
l
i
t
t
o
m
a
o
p
r
m
s
c
u
r
r
e
n
y
y
n
•
h
I
f
l
i
i
l
p
a
s
e
o
c
n
c
a
d
l
t
e
e
o
p
m
e
n
v

Enhancing the sco portfolio op p e of the pharmaceutical

EVT Innovate and EVT Inntegrate - early assets

I
d
i
i
t
n
c
a
o
n		 P
t
a
r
n
e
r		 S
t
t
a
s
u		 N
i
l
t
t
e
m
e
s
o
n
e
x		 C
i
l
o
m
m
e
r
c
a
s
E
E
d
d
i
i
i
i
t
t
n
o
m
e
r
o
s
s		 B
a
y
e
r		 P
l
i
i
l
r
e-
c
n
c
a		 P
P
l
l
i
i
i
i
l
l
r
e-
c
n
c
a		 f
U
€
1
2
l
l
t
t
t
t
p
r
o
n
m
o
a
v
a
u
e
u
p
o
;
€
5
8
0
l
i
t
a
p
p
r
o
x.
m
r
o
y
a
e
s
;
U
d
i
l
d
n
s
c
o
s
e		 i
N
t
o
v
a
r
s		 P
l
i
i
l
r
e-
c
n
c
a		 P
h
I
I
l
i
t
a
s
e
c
o
m
p
e
o
n		 f
f
U
h
d
i
t
t,
p
r
o
n
p
a
m
e
n
r
e
s
e
a
r
c
n
n
g
y
u
i
l
d
l
i
t
t
t
m
e
s
o
n
e
p
a
y
m
e
n
s
a
n
r
o
y
a
e
s
V
i
a
r
o
s
u		 B
h
i
o
e
r
n
g
e
r
i
I
l
h
n
g
e
e
m		 P
l
i
i
l
r
e-
c
n
c
a		 C
l
i
i
l
d
i
d
t
n
c
a
c
a
n
a
e		 M
i
l
l
i
t
t,
t
e
s
o
n
e
p
a
m
e
n
r
o
a
e
s
y
y
P
i
a
n		 P
f
i
e
r
z		 P
l
i
i
l
r
e-
c
n
c
a		 P
h
I
t
t
a
s
e
s
a
r		 \$
M
i
l
h
1
7
0
t
t
e
s
o
n
e
s
m
o
r
e
a
n
m
,
d
b
l
d
d
i
i
i
i
l
i
t
t
t
o
u
e-
g
g
r
o
y
a
e
s
T
2
D
i
b
t
p
e
a
e
e
s
y
S
I
l
i
i
i
t
n
s
u
n
e
n
s
z
e
r		 B
h
i
o
e
r
n
g
e
r
i
I
l
h
n
g
e
e
m		 R
h
e
s
e
a
r
c		 P
l
i
i
l
r
e-
c
n
c
a		 f
U
€
2
3
i
l
i
i
i
t
7
t
t
p
o
m
m
e
s
o
n
e
s,
s
g
n
c
a
n
l
i
t
r
o
a
e
s
y
C
B
t
r
e
e
a
u
T
d
D
i
b
1
2
t
y
p
e
a
n
a
e
e
s		 J
a
n
s
s
e
n
P
h
i
l
t
a
r
m
a
c
e
u
c
a
s		 R
h
e
s
e
a
r
c		 P
l
i
i
l
r
e-
c
n
c
a		 \$
U
f
h
8
t
t
p
r
o
n
m
;
r
e
s
e
a
r
c
p
a
y
m
e
n
;
u
p
\$
i
l
d
3
0
0
t
t
t
o
m
m
e
s
o
n
e
s
p
e
r
p
r
o
u
c
;
l
i
t
r
o
y
a
e
s
T
1
d
2
D
i
b
t
p
e
a
n
a
e
e
s
y
E
V
T
0
7
7		 /
M
d
I
e
m
m
u
n
e
A
Z
t
s
r
a
e
n
c
a		 R
h
e
s
e
a
r
c		 P
l
i
i
l
r
e-
c
n
c
a		 f
U
€
2
4
i
i
l
l
i
i
i
t
5
t
t
t
p
o
m
m
m
e
e
s
s
o
o
n
n
e
e
s
s,
s
g
n
c
a
n
l
i
t
r
o
a
e
s
y
C
N
h
r
e
e
p
r
o
n
u
K
i
d
d
i
n
e
s
e
a
s
e
s
y		 H
d
a
r
a
r
v		 R
h
e
s
e
a
r
c		 P
i
t
a
r
n
e
r
n
g		 O
p
e
n

rolledd over into Janssen deal

"Win – Win – Win" situation

C
B
t
u
r
e
e
a
t
e
r
m
s		 \$
\$
(
U
f
8
i
l
i
l
2
0
0
3
0
0
d
l
i
i
l,
t
t
t
t
t
t
p
r
o
n
m
p
o
e
n
a
m
e
s
o
n
n
e
s
p
o
m
p
e
r
p
r
o
c
p
r
e
-c
n
c
a
u
u
•
-
,
)
l
i
i
l,
l
i
l
t
c
n
c
a
r
e
g
u
a
o
r
y,
c
o
m
m
e
r
c
a
S
i
i
f
i
l
i
t
t
g
n
c
a
n
r
o
a
e
s
y
•
R
h
t
e
s
e
a
r
c
p
a
y
m
e
n
s
•
i
/
i
/
i
W
W
W
n
n
n
i
l
l
a
a
n
c
e		 f
J
A
i
i
i
l
b
i
l
i
d
l
l
l
l
d
i
d
t-
a
n
s
s
e
n
c
c
e
s
s
n
g
r
s
n
-c
a
s
s
s
o
o
g
c
s
a
n
s
m
a
m
o
e
c
u
e
s
c
o
v
e
r
y
a
n
:
•
f
d
l
l
d
i
i
d
i
b
t
t
t
t
e
v
e
o
p
m
e
n
p
a
o
r
m
a
n
e
x
p
e
e
r
s
e
n
a
e
e
s
E
E
d
i
l
d
h
i
i
b
l
l
i
h
i
h
l
i
i
b
i
d
t
t
t
t
t
t
t
v
o
e
c
p
a
n
n
g
e
a
e
r
s
p
n
e
a
c
e
r
e
g
e
n
e
r
a
o
n
g
s
s
s
s
e
e
m
m
a
a
c
c
n
a
s
e
:
x
y
y
y
u
•
–
,
d
h
i
h
b
l
l
l
i
i
t
t
t
a
n
c
o
m
p
r
e
e
n
s
e
a
p
p
r
o
a
c
o
o
e
a
c
e
r
e
p
c
a
o
n
v
H
d
A
l
i
d
l
f
i
i
i
i
h
b
i
i
l
i
d
t
t
t
t
a
r
a
r
c
c
e
e
r
a
n
g
e
e
o
p
m
m
e
n
o
n
n
o
a
e
s
c
e
n
c
e
g
c
o
m
m
e
r
c
a
p
s
e
v
:
v
v
v
w
u
•
S
i
i
t
t
t
a
r
n
g
p
o
n
f
i
i
t
o
r
n
n
o
v
a
o
n
f
f
i
i
d
e
c
e
n
c
y
a
n
l
t
e
x
e
r
n
a
i
i
t
n
n
o
v
a
o
n		 O
i
l
l
i
l
f
d
i
l
b
i
h
i
d
t
t
t
t
t
t
t
t
t
p
m
a
r
a
n
s
a
o
n
a
s
r
a
e
g
y
o
o
r
a
c
a
e
m
a
o
r
e
a
r
y
o
e
c
e
a
s
a
s
a
r
g
e
s
g
e
•
i
d
i
l
h
d
i
f
t
t
t
m
m
e
a
e
o
n
p
p
a
r
m
a
g
g
r
a
e
n
n
r
a
s
r
c
r
e
s
y
y
u
u
f
U
i
d
l
h
i
d
i
i
i
h
P
h
t
t
t
n
q
u
e
e
a
a
p
p
r
o
a
c
n
n
g
r
a
a
c
o
n
w
a
r
m
a
•

Agenda

  • •Highlights Q3 2012
  • • Action Plan 2016 – Innovation Efficiency
  • EVT Execute
  • EVT Integrate
  • EVT Innovate

• Financial performance e &growth outlook

The momentum off H1 maintained into Q3

First 9 months 2012: Conddensed consolidated statement of operations (IFRS)

in € m

Y
d
Q
Q
3
2
0
1
2
t		 Y
d
Q
3
2
0
1
1
t		 %
2
0
1
1
s
v
R
e
v
e
n
u
e
s		 6
6
4
2		 )
1
9
5
7		 8
%
G
i
r
o
s
s
m
a
r
g
n		 3
6
6
4
%		 4
8
4
%
R
&
D
e
p
e
n
s
e
s
x
•		 6
6
1		 6
8		 (
)
1
0
%
S
G
&
A
e
p
e
n
s
e
s
x
•		 1
2
3		 1
1
5		 7
%
A
i
i
t
t
m
o
r
s
a
o
n
•		 2
2
0		 )
2
1
2
f
R
l
i
i
t
e
e
r
s
a
o
m
p
a
r
m
e
n
v
•		 - )
3
(
)
1
5
O
h
(
i
)
t
t
e
r
o
p
n
c
o
m
e
e
p
e
n
s
e
s
n
e
x
•
,		 0
0
2		 1
4
O
i
i
t
p
e
r
a
n
g
n
c
o
m
e		 2
2
9		 9
5		 (
)
0
%
7
i
N
t
e
n
c
o
m
e		 7
7
5		 9
2		 (
)
1
8
%

Strong Q3 2012 de CureBeta deal espite conservative recognision of

Q3 2012: Condensed cons olidated statement of operations (IFRS)

Q
3
3
2
0
1
2		 Q
3
2
0
1
1		 %
2
0
1
1
v
s
R
e
e
n
e
s
v
u		 2
2
2
2		 )
1
2
6
3		 (
)
1
6
%
G
i
r
o
s
s
m
a
r
g
n		 3
8
9
%		 4
8
%
5
R
&
D
e
p
e
n
s
e
s
x
•		 2
2		 2
1		 2
%
S
G
&
A
e
p
e
n
s
e
s
x
•		 4
2		 3
9		 8
%
A
i
i
t
t
m
o
r
s
a
o
n
•		 0
8		 0
6
f
R
l
i
i
t
e
v
e
r
s
a
o
m
p
a
r
m
e
n
•		 - )
2
(
)
1
5
O
h
(
i
)
t
t
e
r
o
p
n
c
o
m
e
e
p
e
n
s
e
s
n
e
x
•		 (
(
)
0
1		 0
7
O
i
i
t
p
e
r
a
n
g
n
c
o
m
e		 5
1		 8
6		 (
)
8
2
%
N
i
t
e
n
c
o
m
e		 5
9		 8
4		 (
)
3
0
%

Strong underlying g ygmargins revenue growth and solid gross g g

Revenues & gross margins s for the first nine months 2012

in € m

Strong operating a and net result

Results for the first nine mmonths 2012

Focused R&D investable SG&A expe estments for long-term growth, g g enses

First nine months 2012: RR&D and SG&A

in € m

On track to achievve guidance (> € 60 m at end 2012)

First 9 months 2012: Conddensed consolidated statements of cash flows (IFRS)

Liquidity in € m

)
1
2
0
1
1		 )
1
2
0
1
2
N
h
i
d
d
b
(
d
i
)
t
e
c
a
s
p
r
o
e
s
e
n
v
y
u		 C
h
i
i
l
t
t
t
a
s
g
e
n
e
r
a
e
o
p
e
r
a
n
g
r
e
s
v
u
•
O
i
i
i
i
t
t
t
p
e
r
a
n
g
a
c
v
e
s
•		 9
9
1		 0
3		 f
f
b
t
o
s
e
y
:
i
i
i
i
I
t
t
t
n
v
e
s
n
g
a
c
v
e
s
•		 3
3
2
-		 1
4
0		 f
I
i
k
i
i
l
t
n
c
r
e
a
s
e
n
w
o
r
n
g
c
a
p
a
o
•
€
9
0
d
i
d
t
m
u
e
o
n
c
r
e
a
s
e
i
i
i
i
i
F
t
t
n
a
n
c
n
g
a
c
v
e
s
•		 0
0
8
-		 2
8		 d
i
i
l
t
t
t
r
e
v
e
n
u
e
s
o
u
s
a
n
n
g
m
e
s
o
n
e
,
f
l
t
t
p
a
y
m
e
n
s
p
a
y
m
e
n
o
a
n
n
u
a
f
f
E
h
d
i
t
x
c
a
n
g
e
r
a
e
e
r
e
n
c
e		 0
0
2		 0
6		 ,
b
o
n
s
e
s
u
C
h
d
h
i
l
d
f
i
d
t
t
a
s
a
n
c
a
s
e
q
a
e
n
s
a
e
n
o
p
e
r
o
u
v		 2
6
6
3		 5
5
3
I
t
t
+
n
e
s
m
e
n
s
v		 3
4
4
1		 2
0
4		 f
C
C
I
l
d
d
i
i
i
t
n
c
c
u
u
e
e
s
s
s
s
g
g
n
c
c
a
a
n
a
a
p
p
e
e
x
•
i
f
€
6
3
t
t
n
v
e
s
m
e
n
s
o
m
L
i
i
d
i
d
f
i
d
t
t
q
u
y
a
e
n
o
p
e
r
o
=		 6
0
0
4		 5
5
9		 I
l
d
i
i
t
t
n
c
e
s
n
e
s
m
e
n
n
u
v
•
L
i
i
d
i
b
i
i
f
i
d
t
t
q
a
e
g
n
n
n
g
o
p
e
r
o
u
y		 7
0
0
4		 6
2
4		 4
4
A
A
i
i
b
b
d
d
f
€
2
2
0
0
t
t
n
n
o
o
o
m
m
y
y
-
/
N
i
d
i
l
i
i
d
i
t
t
e
n
c
r
e
a
s
e
e
c
r
e
a
s
e
n
q
u
y		 1
0
0
0
-		 6
5
-		 M
i
i
t
t
t
o
e
m
e
n
n
n
e
s
m
e
n
s
v
v
•

Delay of Q4 milest tones drops profitability guidance

Guidance overview

i
€
n
m		 G
i
d
u
a
n
n
c
e
O
2
0
1
2
t
c		 G
i
d
u
a
n
c
e
M
2
0
1
2
a
r		 F
Y
2
0
1
1
R
e
v
e
n
u
e
s		 8
8
9
0
-		 8
8
9
0
-		 8
0
1
)
1
O
A
d
j
d
i
i
t
t
u
s
e
p
e
r
a
n
g
n
c
o
m
e		 L
h
2
0
1
1
t
e
s
s
a
n
n		 I
d
m
p
r
o
e
o
e
r
v
v
2
0
1
1		 8
5
I
i
i
t
t
t
n
n
o
v
a
o
n
n
v
e
s
m
e
n
s
(
)
R
&
D
E
x
p
e
n
s
e
s		 A
1
0
p
p
r
o
x		 A
1
0
p
p
r
o
x		 8
4
C
i
t
t
a
p
e
x
n
v
e
s
m
e
n
s		 A
1
0
p
p
r
o
x		 M
h
1
0
t
o
r
e
a
n		 8
1
L
i
i
d
i
i
d
d
t
t
q
a
p
e
r
o
e
n
u
y		 A
b
6
0
o
v
e		 A
b
6
0
o
e
v		 6
2
4

Action Plan 2016 –Gaining Momentum

Outlook and next steps for r 2012 ff

Key milestones for 2012

E
V
T
E
t
1
x
e
c
u
e		 D
b
l
d
i
i
h
2
0
1
2
2
0
1
6
t
t
o
e
g
r
e
e
n
e
g
r
o
o
u
v
u
w
•
-
E
i
f
i
i
l
l
i
t
p
a
n
s
o
n
s
c
c
e
s
s
o
e
s
n
g
a
a
n
c
e
s
x
u
x
x
•
S
f
i
i
i
l
d
l
i
h
j
h
t
t
t
g
n
c
a
n
o
n
g
e
r
m
e
a
a
s
w
m
a
o
r
p
a
r
m
a
•
-
E
V
T
I
t
t
2
n
e
g
r
a
e		 /
/
A
l
i
i
f
i
i
d
d
h
l
d
d
i
l
l
i
(
(
B
)
)
2
t
t
t
t
t
t
t
t
t
e
a
s
s
g
g
n
c
c
a
a
n
n
e
n
e
g
r
a
a
e
e
e
e
c
c
n
o
o
o
o
g
g
s
s
e
e
a
a
s
s
e
e
a
a
a
n
c
c
e
e
s
s
a
a
e
e
r
w
w
y
y
y
y
•
D
l
i
i
i
f
i
d
l
d
l
i
i
l
/
l
i
i
l
i
l
t
t
t
e
e
r
s
g
n
c
a
n
a
n
a
a
c
c
e
e
r
a
e
p
r
e
-c
n
c
a
c
n
c
a
m
e
s
o
n
e
s
v
•
S
f
h
i
l
i
i
i
i
t
t
t
o
w
o
p
e
r
a
o
n
a
s
y
n
e
r
g
g
e
s
o
r
e
c
e
n
a
c
q
u
s
o
n
s
•
(
(
)
)
E
d
f
f
i
i
l
l
l
f
f
i
A
A
i
i
b
b
d
d
i
i
t
t
t
p
a
n
o
e
r
n
g
n
o
a
r
g
g
e
r
m
o
e
c
e
s
o
e
r
n
g
e
e
g
g
n
n
o
o
e
e
s
s
x
u
•
E
V
T
I
t
3
n
n
o
a
e
v		 A
l
i
d
l
f
l
1
t
t
t
t
t
e
a
s
s
r
a
e
g
c
e
a
o
r
e
a
r
a
s
s
e
s
y
•
C
(
(
C
)
i
l
i
i
i
X
t
o
m
m
e
r
c
a
s
e
n
n
o
v
a
o
o
n
e
e
g
g
u
r
e
•
,
…
P
h
I
I
I
d
i
D
i
P
d
P
h
I
I
i
h
i
A
D
d
2
7
7
t
t
t
t
t
a
s
e
a
a
n
a
e
p
p
a
n
a
s
e
s
a
r
w
n
p
r
o
u
c
•
d
l
h
i
t
t
e
v
e
o
p
m
e
n
p
a
r
n
e
r
s
p
p

Your contact:

Dr Mario Polywka Chief Operating Officer

+44 (0)1235.44 16 76 +44 (0)1235.86 31 39 Fax [email protected]

More from Evotec SE

Capital/Financing Update 2026
May 12
Regulatory Filings 2026
May 7
Regulatory Filings 2026
May 6
Interim / Quarterly Report 2026
May 6
Director's Dealing 2026
May 5
Regulatory Filings 2026
May 5
Regulatory Filings 2026
May 4
Regulatory Filings 2026
Apr 30
Report Publication Announcement 2026
Apr 29
Major Shareholding Notification 2026
Apr 28
View all filings →